SentoClone AB
🇸🇪Sweden
SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma
Phase 2
- Conditions
- Malignant Melanoma
- Interventions
- Biological: SentoClone®
- First Posted Date
- 2009-10-07
- Last Posted Date
- 2010-02-05
- Lead Sponsor
- SentoClone AB
- Target Recruit Count
- 140
- Registration Number
- NCT00991250
- Locations
- 🇸🇪
Norrlands Universitetssjukhus, Umeå, Västerbottens Län, Sweden
🇸🇪Karolinska Sjukhuset, Stockholm, Stockholms Län, Sweden
🇸🇪Lunds Universitetssjukhus, Lund, Skåne, Sweden
© Copyright 2025. All Rights Reserved by MedPath